Thus, BCG immunotherapy for HCC is distinctly different from other immunotherapies, such as anti‐PD‐1, which essentially only rely on CD8+ T cells.[35] In addition, BCG demonstrated superior efficacy than anti‐PD‐1 in reducing tumor burden, as evidenced by the L/B ratio and histological assessments (Figure 3C). Here, CD8A is linked to hepatocellular carcinoma.